This is an old revision of this page, as edited by Citation bot 1 (talk | contribs) at 18:29, 11 September 2010 (Citations: Formatted dashes. You can use this bot yourself. Report bugs here.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 18:29, 11 September 2010 by Citation bot 1 (talk | contribs) (Citations: Formatted dashes. You can use this bot yourself. Report bugs here.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Names | |
---|---|
IUPAC name (2S)-2-amino]-4-methylpentanoic acid | |
Other names Bestatin; N--L-leucine | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
ECHA InfoCard | 100.055.917 |
PubChem CID | |
CompTox Dashboard (EPA) | |
SMILES
| |
Properties | |
Chemical formula | C16H24N2O4 |
Molar mass | 308.378 g·mol |
Melting point | 245 °C (dec.) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references |
Ubenimex (INN), also known as bestatin, is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase , aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
References
- N-((2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl)-L-leucine at Sigma-Aldrich
- Umezawa,H., Aoyagi,T., Suda,H., Hamada,M. & Takeuchi,T. (1976). "Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes" (29): 97–99.
{{cite journal}}
: Cite journal requires|journal=
(help)CS1 maint: multiple names: authors list (link) - Muskardin,D.T., Voelkel,N.F. & Fitzpatrick,F.A. (1994). "Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase" (48): 131–137.
{{cite journal}}
: Cite journal requires|journal=
(help)CS1 maint: multiple names: authors list (link) - K Sekine, H Fujii and F Abe (1999). "Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines". 13 (5): 729–734.
{{cite journal}}
: Cite journal requires|journal=
(help) - Hirayama, Y; Sakamaki, S; Takayanagi, N; Tsuji, Y; Sagawa, T; Chiba, H; Matsunaga, T; Niitsu, Y (2003). "Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival". Gan to kagaku ryoho. Cancer & chemotherapy. 30 (8): 1113–8. PMID 12938265.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |